Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer

Fineline Cube Mar 19, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...

Company Drug

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial

Fineline Cube Mar 19, 2025

Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...

Company Deals

Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation

Fineline Cube Mar 19, 2025

On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the...

Company

Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform

Fineline Cube Mar 19, 2025

Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...

Company Medical Device

GE Healthcare Launches AltiX AI.i Edition for Enhanced Cardiac Procedures

Fineline Cube Mar 18, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...

Company

WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion

Fineline Cube Mar 18, 2025

China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...

Company Deals

Eisai Launches JPY16 Billion Tender for EcoNaviSta to Expand Dementia Care Ecosystem

Fineline Cube Mar 18, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced a tender offer valued at JPY16 billion (USD107...

Company Drug

Bayer’s Kerendia Gets FDA Priority Review for Heart Failure with Preserved Ejection Fraction

Fineline Cube Mar 18, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that a supplementary New Drug Application (sNDA) for...

Policy / Regulatory

HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process

Fineline Cube Mar 18, 2025

HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...

Company Medical Device

IceCure Medical Secures Chinese Patent for Cryogenic System Connector

Fineline Cube Mar 18, 2025

Israel-based IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving patent authorization from the China National Intellectual...

Company

FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development

Fineline Cube Mar 18, 2025

US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...

Company Deals

Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio

Fineline Cube Mar 18, 2025

Japan-based Taiho Pharmaceutical Co., Ltd. announced plans to fully acquire Araris Biotech AG, a Swiss...

Company Drug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Fineline Cube Mar 18, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational...

Company Medical Device

Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA

Fineline Cube Mar 18, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced receiving market approval from the National Medical Products...

Company Deals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Fineline Cube Mar 18, 2025

Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...

Company Drug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Fineline Cube Mar 18, 2025

Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Fineline Cube Mar 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...

Company Drug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

Fineline Cube Mar 18, 2025

China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...

Company Deals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

Fineline Cube Mar 17, 2025

On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....

Company Deals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies

Fineline Cube Mar 17, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...

Posts pagination

1 … 246 247 248 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.